KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Common Equity (2016 - 2025)

Historic Common Equity for Edwards Lifesciences (EW) over the last 17 years, with Q3 2025 value amounting to $10.2 billion.

  • Edwards Lifesciences' Common Equity rose 617.6% to $10.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $10.2 billion, marking a year-over-year increase of 617.6%. This contributed to the annual value of $10.1 billion for FY2024, which is 4975.89% up from last year.
  • As of Q3 2025, Edwards Lifesciences' Common Equity stood at $10.2 billion, which was up 617.6% from $10.6 billion recorded in Q2 2025.
  • In the past 5 years, Edwards Lifesciences' Common Equity registered a high of $10.6 billion during Q2 2025, and its lowest value of $4.7 billion during Q1 2021.
  • Moreover, its 5-year median value for Common Equity was $6.4 billion (2023), whereas its average is $7.2 billion.
  • As far as peak fluctuations go, Edwards Lifesciences' Common Equity tumbled by 50.04% in 2022, and later soared by 4975.89% in 2024.
  • Over the past 5 years, Edwards Lifesciences' Common Equity (Quarter) stood at $5.8 billion in 2021, then fell by 0.5% to $5.8 billion in 2022, then grew by 15.72% to $6.7 billion in 2023, then soared by 49.76% to $10.1 billion in 2024, then rose by 1.41% to $10.2 billion in 2025.
  • Its last three reported values are $10.2 billion in Q3 2025, $10.6 billion for Q2 2025, and $10.2 billion during Q1 2025.